FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject	STATEME
to Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	Fi

## ENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  INGRAM ROBERT ALEXANDER						2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC BCRX									ationship k all app Direc	,	ng Pe	rson(s) to Is	
(Last) (First) (Middle) 280 S. MANGUM STREET SUITE 350						3. Date of Earliest Transaction (Month/Day/Year) 05/28/2021									Office below	er (give title v)		Other ( below)	specify
(Street) DURHA (City)			7701 Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)      5. Individual or Joint/Group Filing (Check Application)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person									on					
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or E	Benefi	cially	y Own	ed			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day					Execution Da			Code (Instr.		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			4 and Secur Benet		cially   Following	Forn (D) c	wnership n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code V		Amount	(A) (D)	or Pri	се	Transa	action(s) 3 and 4)			(				
Common Stock <sup>(1)</sup> 05/28/2					2021				A		1,188	A	\$1	L <b>5.</b> 77	.77 76,201			D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date,		Code ( 8)	ransaction of Code (Instr. Derivative		vative irities uired r osed ) r. 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Exercisable Expiration Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)  Amount or Number of Title Shares		De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

## **Explanation of Responses:**

 $1. \ Shares of \ Common \ Stock \ is sued to the \ reporting \ person \ in \ lieu \ of \ quarterly \ cash \ Board \ Member \ retainer \ of \$18,750.$ 

/s/ Alane P. Barnes, by power of attorney

06/01/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.